Delphine Compere

Delphine Compere has extensive experience in the field of medicinal chemistry and drug discovery. Delphine is currently working as the Head of Medicinal Chemistry at Coave Therapeutics since 2022. Prior to that, they served as the Chief Scientific Officer at Temisis Therapeutics from 2021 to 2022.

From 2019 to 2021, Delphine worked at Recherche & Innovation where they engaged in drug discovery, contract research, and consulting activities. Before that, they held the position of Head of Medicinal Chemistry at Quantum Genomics from 2015 to 2019, where they focused on developing drugs for cardiovascular diseases.

Delphine also has experience in drug discovery for antiviral agents, specifically targeting the Human Papilloma Virus (HPV) as the Head of Chemistry at Anaconda Pharma from 2005 to 2015. Prior to that, they worked as a Senior Scientist in Chemistry at Eurofins-Cerep, where they collaborated with Sanofi-Synthelabo.

Earlier in their career, Delphine worked as a Senior Scientist in Medicinal Chemistry at Pfizer from 1999 to 2004. Delphine also had teaching and research experience at Université Paris Descartes, where they conducted peptidomimetics research and taught chemistry tutorials from 1998 to 1999.

Delphine started their career with a Post-Doctoral position at Imperial College London, focusing on combinatorial chemistry and developing new methodologies on solid support. Delphine holds a Ph.D. in Organic Chemistry from CNRS - Centre national de la recherche scientifique, Institut de Chimie des Substances Naturelles, where they conducted research on the total synthesis of Lobelia alkaloid for the activation of nicotinic cholinergic receptors in the central nervous system.

Delphine Compere completed their Ph.D. in Organic Chemistry from Paris-Sud University (Paris XI) between 1993 and 1996. In 2020 and 2021, they pursued a University Degree - 3rd cycle in Biological and Medical Engineering at Sorbonne Medical School.